Changes in ovarian cancer survival during the 20 years before the era of targeted therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Changes in ovarian cancer survival during the 20 years before the era of targeted therapy

Published:2018-05-29 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Lee Jung-Yun,Kim Sunghoon,Kim Young Tae,Lim Myong Cheol,Lee Boram,Jung Kyu-Won,Kim Jae Weon,Park Sang-Yoon,Won Young-Joo

Funder

National Cancer Center

Yonsei University College of Medicine

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-4498-z.pdf

Reference36 articles.

1. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49(2):292–305.

2. Kim SI, Lim MC, Lim J, Won YJ, Seo SS, Kang S, Park SY. Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. J Gynecol Oncol. 2016;27(1):e5.

3. Lee JY, Kim EY, Jung KW, Shin A, Chan KK, Aoki D, Kim JW, Low JJ, Won YJ. Trends in gynecologic cancer mortality in east Asian regions. J Gynecol Oncol. 2014;25(3):174–82.

4. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108(3 Pt 1):521–8.

5. Wright JD, Chen L, Tergas AI, Patankar S, Burke WM, Hou JY, Neugut AI, Ananth CV, Hershman DL. Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol. 2015;125(6):1345–52.

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancer;International Journal of Gynecologic Cancer;2024-09-04

2. Asian American sub-ethnic disparities and trends in epithelial ovarian cancer diagnosis, treatment and survival;Ethnicity & Health;2024-07-05

3. OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer;Future Oncology;2024-06-28

4. The Impact of Neoadjuvant Chemotherapy on Ovarian Cancer Tumor Microenvironment: A Systematic Review of the Literature;International Journal of Molecular Sciences;2024-06-27

5. Evaluation of the efficacy of marine natural products against PARP-1/2 proteins in high-grade serous ovarian cancer: insights into MD and SMD simulations;Journal of Biomolecular Structure and Dynamics;2024-06-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3